Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: Real life survey from a Spanish registry.
Maria Dolores Ibáñez SandínCarmelo EscuderoRocío Candón MorilloEva M LasaEva Marchán-MartínSilvia Sánchez-GarcíaSoledad TerradosCarlos González DíazSonsoles JusteAntonio MartorellVanessa Gázquez GarcíaAntonio Ramírez JiménezÁngel AbellánMaría D Martos CalahorroAna I TabarJoan BartraRosa García RodríguezCatalina Gómez GalánMaría Flora Martín-MuñozJosé Meseguer ArceJuan C MirallesAna M Montoro de FranciscoPaloma Poza GuedesPablo Rodríguez Del Ríonull nullPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021)
Milk oral immunotherapy initiated under omalizumab allows the desensitization of subjects with severe cow's milk allergy even after omalizumab discontinuation. However, discontinuation of omalizumab can lead to severe AE and should be carefully monitored.
Keyphrases